Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05032183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05015335
- Locations
- 🇨🇳
Peking University Medical College Hospital, Beijing, China
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 50
- Registration Number
- NCT05008887
An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04967950
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
- Conditions
- Diamond-Blackfan AnemiaHereditary Sideroblastic AnemiaParoxysmal Nocturnal HemoglobinuriaShwachman-Diamond SyndromeHematologic Neoplasm With Germline GATA2 MutationHematologic Neoplasm With Germline SAMD9 MutationHematologic Neoplasm With Germline SAMD9L MutationBone Marrow Failure SyndromeCongenital Amegakaryocytic Thrombocytopenia
- Interventions
- Drug: TreosulfanDrug: Fludarabine PhosphateDrug: TacrolimusDrug: MethotrexateBiological: Lapine T-Lymphocyte Immune GlobulinProcedure: Peripheral Blood Stem Cell TransplantationProcedure: Allogeneic Bone Marrow TransplantationOther: Quality-of-Life AssessmentProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: X-Ray ImagingProcedure: Computed Tomography
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04965597
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cohen Children's Hospital of NY, Queens, New York, United States
MTX and Steroid as First-line Therapy for aGVHD
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 157
- Registration Number
- NCT04960644
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
MTX and Steroid for III-IV aGVHD Treatment
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04958538
- Locations
- 🇨🇳
Peking University Institute of Hematology,, Beijing, Beijing, China
Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT04944524
- Locations
- 🇨🇳
Department of Rheumatology in Zhongshan hospital, Fudan University, Shanghai, Shanghai, China
Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-11-23
- Target Recruit Count
- 17
- Registration Number
- NCT04934579
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 338
- Registration Number
- NCT04909801
- Locations
- 🇮🇹
Local Institution - 0083, Catania, Italy
🇮🇹Local Institution - 0077, Pavia, Italy
🇺🇸Local Institution - 0036, Fullerton, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.